Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Avalo Therapeutics (AVTX) has disclosed Receivables for 8 consecutive years, with $44000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Receivables fell 97.62% year-over-year to $44000.0, compared with a TTM value of $44000.0 through Jun 2023, down 97.62%, and an annual FY2022 reading of $1.9 million, down 60.01% over the prior year.
  • Receivables was $44000.0 for Q2 2023 at Avalo Therapeutics, down from $1.9 million in the prior quarter.
  • Across five years, Receivables topped out at $8.2 million in Q1 2019 and bottomed at $44000.0 in Q2 2023.
  • Average Receivables over 5 years is $3.9 million, with a median of $4.3 million recorded in 2020.
  • The sharpest move saw Receivables soared 32.68% in 2020, then crashed 97.62% in 2023.
  • Year by year, Receivables stood at $5.2 million in 2019, then decreased by 16.35% to $4.4 million in 2020, then grew by 9.44% to $4.8 million in 2021, then tumbled by 60.01% to $1.9 million in 2022, then tumbled by 97.71% to $44000.0 in 2023.
  • Business Quant data shows Receivables for AVTX at $44000.0 in Q2 2023, $1.9 million in Q4 2022, and $1.3 million in Q3 2022.